Slide 1: Vimta Labs Limited
VimLa Vimta Labs Limited Registered Office 142, IDA Phase II, Cherlapally Hyderabad-500 051 ,Telangana, India T: +91 4027264141 F : +91 40 2726 3657 Driven by Quality. Inspired by Science. VLL\SE\007\2025 26 Date: 28.04.2025 B S E Limited, Asst Vice President, P J Towers, Dalal Street, National Stoc
Slide 2: Investor Presentation Q4 & FY25
Vimta Labs Limited Investor Presentation Q4 & FY25
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Agenda
Q4 & FY25 Earnings Company Overview TTTTT TT Industry Landscape CTTTTTTT Our Competitive Advantage Way Forward
Slide 5: Q4 & FY25 Earnings
Q4 & FY25 Earnings Q4 & FY25 Highlights FY25 Business Updates Key Metrics: Q4 & FY25 Profit & Loss Statement Financial Track Record Shareholding Pattern
Slide 6: Q4 FY25 Highlights
Q4 FY25 Highlights Rs 961 Mn Rs 347 Mn Rs 250 Mn Margin 36.1% Total Income EBITDA PBT ₹ Rs 8.22 Rs 39 Mn Rs 183 Mn Margin 19.1% EPS CAPEX Outflow PAT 5
Slide 7: FY25 Highlights
FY25 Highlights Rs 3,482 Mn Rs 1262 Mn Rs 890 Mn Margin 36.2% Total Income EBITDA PBT T Rs 30.02 Rs 668 Mn Rs 791 Mn Margin 19.2% EPS CAPEX Outflow PAT 0.02x Rs 85 Mn Rs 329 Mn (MTTTT 31TT (MTTTT 31TT 2025) Debt to Equity Ratio 2025) Total Debt Cash and Cash Equivalents 6
Slide 8: FY25 Business Updates
FY25 Business Updates Successful regulatory audits from various regulatory authorities: USFDA (Clinical GLP); European Medicines Agency (cGMP – human health and animal health); Turkey (cGMP); Kazakhastan (GCP), NGCMA (OECD-GLP) and CDSCO (GCP, Medical Devices). Forayed into Clinical trial servic
Slide 9: Key Metrics: Q4 FY25
Key Metrics: Q4 FY25 Total Income EBIDTA & EBIDTA Margin PAT & PAT Margin Basic EPS (In ₹) (In ₹ Mn) (In ₹ Mn, %) (In ₹ Mn, %) EBIDTA EBIDTA Margin PAT PAT Margin 31.4% 31.9% 31.2% YoY YoY 200 YoY 19 % 19 % 175 19.2 19 % 150 % 37.6% 19 % 36.1% 125 36.0% 19 % 5 100 19 % 75 19 % 50 19.1 19.1 19 % 25 %
Slide 10: Key Metrics: FY25
Key Metrics: FY25 Total Income EBIDTA & EBIDTA Margin PAT & PAT Margin Basic EPS (In ₹) (In ₹ Mn) (In ₹ Mn, %) (In ₹ Mn, %) EBIDTA EBIDTA Margin PAT PAT Margin 19.1% 29.1% 725 36.8% 20 % YoY YoY 700 675 YoY 650 19 % 625 600 19.2% 575 36.2% 19 % 550 33.4% 525 500 18 % 475 450 425 16.7 400 18 % 375 %
Slide 11: Financial Track Record
Financial Track Record TOTAL INCOME (₹ Mn) PROFITABILITY (₹ Mn) EBITDA & EBITDA Margin PAT & PAT Margin 36% 19% 33% 17% 29% 31% 15% 15% 25% 18% 4% 10% 11.2% 25.1% 46.3% 1,837 2,115 2,797 3,216 2,923 3,482 330 538 817 984 977 1,262 214 413 482 488 668 CAGR CAGR 68 CAGR FT20 FT21 FT22 FT23 FT24 FT25 F
Slide 12: Profit & Loss Statement
Profit & Loss Statement Particulars (₹ Mn) Q4 FY25 Q4 FY24 YoY (%) Q3 FY25 QoQ(%) FY25 FY24 YoY (%) Revenue from Operations 944.4 727.3 899.0 3,439.8 2,886.0 Other Income 16.4 3.8 12.0 42.4 37.1 Total Income 960.8 731.2 31.4% 911.0 5.5% 3,482.2 2,923.1 19.1% Material and Testing Costs 181.6 132.9 20
Slide 13: Shareholding Pattern
Shareholding Pattern Shareholding as on 31st March 2025 Share Information as on 31st March 2025 NSE Ticker VIMTALABS BSE Ticker 524394 Market Cap (INR Cr) 2,223.67 OTTTTT % free-float 63.30% 58.2% PTTTTTTTT 36.7% Free-float market cap (INR Cr) 1,407.57 Total Debt (INR Mn) 85 Cash & Cash Equivalents
Slide 14: Company Overview
Company Overview Vimta at a Glance Our Journey Services Geographical Presence Management
Slide 15: Vimta at a Glance
Vimta at a Glance Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high-quality, cutting-edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics, sma
Slide 16: Our Journey
Our Journey Infrastructure People Investment Capabilities Revenues Pharma & Biopharma: Discovery & development 2024 600,000+ ft2 1300+ 492 M services; Food; Environment; Electronics Testing 3,216 M Analytical – Pharma, Biopharma & Food; Clinical 2015 400,000+ ft2 1000+ 580 M Research; Preclinical; C
Slide 17: Our offerings
Our offerings Drug discovery and Food & Agri Electronics & Environment development Testing Electricals Testing & services Testing Consultancy 16
Slide 18: Drug discovery and development services
1. Drug discovery and development services Offerings Pharma Analytical Clinical Research Preclinical Research Industry Pharmaceuticals, Biologics, Medical Device, Pharmaceuticals, Biologics, Nutraceuticals, Medical Devices, Animal Health. Agrochemical, Speciality Chemicals Accreditations & Regulator
Slide 19: Food & Agri Testing
2. Food & Agri Testing Industry Food Manufacturing & Processing, Cultivation, Export, Retail, Nutraceuticals, Agro-chemicals, Water & Beverages, Animal Feed No. of Locations 7 (Hyderabad, Mumbai (NFL), Ahmedabad, Bengaluru, Nellore, Nashik, Noida) Accreditations & Regulatory • FSSAI, ISO 17025, BIS,
Slide 20: Electricals & Electronics Testing & Certification
3. Electricals & Electronics Testing & Certification Industry Aviation, Defence, Medical Device, Telecom, Home appliances, Toys, Industrial & control equipment, Consumer electronics, Rail & Automotive, IT, IOT, physical security products, and allied industries No. of Laboratories 1 (Hyderabad) Accre
Slide 21: Environment Testing & Consultancy Services
4. Environment Testing & Consultancy Services Industry Manufacturing and Processing industries, Oil & Gas, Power, Cement, Mining, Infrastructure, etc. No. of Locations 4 (Hyderabad, Chennai, Kolkata and Noida) Accreditations & Regulatory MoEF, ISO 17025, QCI/NABET, OSHAS 45000 Approvals Post proje
Slide 22: Geographical Presence
Geographical Presence Hyderabad (Headquarters) Food Pharma Electronics & Electrical Environment Food Environment Electrical and Electronics Hyderabad Hyderabad Hyderabad Ahmedabad Chennai Noida Noida Mumbai (NFL) Kolkata Nashik Bengaluru Nellore 21
Slide 23: Key Management Team
Key Management Team S P Vasireddi Harita Vasireddi Sreenivas Neerukonda Siva Kambhampati Harriman Vungal Executive Chairman Managing Director Executive Director Chief Financial Officer Executive Director - Operations Dr. S P Vasireddi is a Scientist – Technocrat – Harita has close to 25 years of exp
Slide 24: Industry Landscape
Industry Landscape Market Opportunity Factors Driving Industry Growth
Slide 25: Markets Opportunity: Global
Markets Opportunity Pharmaceutical & Preclinical Food Testing Environment Testing Electronics Testing Biopharmaceuticals 957.6 127.3 40.5 20.2 13.4 (USD Bn) 76.6 Global 11.1 405.5 19.5 6.8 2020 | 2028 2023 | 2028 2022 | 2032 2022 | 2030 2021 | 2031 24
Slide 26: Markets Opportunity: Indian
Markets Opportunity Pharmaceutical & Preclinical Food Testing Environment Testing Electronics Testing Biopharmaceuticals 130 0.9 0.4 1 13.4 0.6 (USD Bn) Indian 0.2 42 0.5 6.8 2021 | 2030 2021 | 2030 2022 | 2027 2021 | 2026 2021 | 2028 25
Slide 27: Factors Driving Industry Growth
Factors Driving Industry Growth Drug Discovery & Food Electrical & Environment Testing Development Testing Electronics Testing Increasing demand for new drug Growing international food Surge in demand for Increase in regulations to innovations, growth in biologics regulations, evolving Indian food c
Slide 28: Our Competitive Advantage
Our Competitive Advantage Our Position in the CRTO Landscape Our Strength
Slide 29: Our Position in the CRTO Landscape
Our Position in the CRTO Landscape Pharma Analytical Food Testing #1 in India #1 in India Customers – 90% of India top 20 Serving 7 of India’s top 10 food companies 36% revenues from overseas The only private EU commission approved lab in India Clinical Research Preclinical Among the most reputed CR
Slide 30: Our Strengths
Our Strengths Compliance Infrastructure Innovations Strong culture of quality and compliance Unparalleled lab infrastructure in the country. Gold Continuous addition of services and evolving LEED certified Vivarium excellence Customer Centricity Knowledge Long term partnerships with Multi-disciplina
Slide 31: Way Forward
Way Forward Our Key Growth Drivers & Strategies
Slide 32: Our Key Growth Drivers & Strategies
Our Key Growth Drivers & Strategies Favourable markets Core business strategies Core operational Best strategies practices Growth momentum Capacity expansions Operational excellence Good corporate governance in markets Service innovations Hiring right talent Risk management Growing d
Slide 33: Thank You
Thank You Vimta Labs Ltd. Siddesh Chawan Chief Financial Officer Siddesh.Chawan@in.ey.com Advait Bhadekar Siva Rama Krishna Kambhampati Advait.Bhadekar@in.ey.com Siva.Kambhampati@vimta.com Registered Office Plot NSE: VIMTALABS Plot #142, IDA Phase 2 Cherlapally, BSE: 524394 Hyderabad Telangana, Indi